NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Quince Therapeutics, Inc. (QNCX) Stock Analysis

Quince Therapeutics, Inc. (QNCX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

QNCX

$31.32

+$0.77 (+2.52%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare QNCX with… →

QNCX Key Statistics

As of Sep 4, 2026
Trading
Open
$30.53
Previous Close
$30.55
Day's Range
30.00–33.40
52-Week Range
15.10–910.00
Volume
37.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.31
Valuation
Market Cap
$31.85M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−214.33
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$83.98M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.02M
1-Year Return
−90.24%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
30.14K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

QNCX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−95.33%
2025+79.14%
2024+78.10%
2023+64.84%
2022−94.95%
2021−54.57%
2020−50.52%
2019 (partial year)+70.69%

As of September 4, 2026.

QNCX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$83.98M—
2024$0.00−$56.83M—
2023$0.00−$31.39M—
2022$0.00−$51.66M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$50.43M−$83.98M—
2024$0.00—−$36.17M−$56.83M—
2023$0.00—−$27.14M−$31.39M—
2022$0.00—−$51.19M−$51.66M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

QNCX Valuation vs Biotechnology Median

Median of 656 stocks
MetricQNCXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Quince Therapeutics, Inc. (QNCX) is capitalised at $31.85M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 38.

The most recent close on file for QNCX is $31.32, dated September 4, 2026. That is +$0.77 (+2.52%) against the previous close. The 52-week range on file runs from $15.10 to $910.00. The latest close sits 107.42% above that 52-week low.

Financial Health

In fiscal 2025, Quince Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $83.98M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −214.33.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.31. Annualized volatility over the trailing 7 years is 162.08%. The trailing one-year price return is −90.24%. Across 5 years the annualized return works out at −72.12%.

Growth & Income

The record shows no dividend for QNCX.

So far in 2026 the price is −95.33%. The strongest complete calendar year on file is 2025 at +79.14%; the weakest is 2022 at −94.95%. Of the 6 complete calendar years on file, 3 finished higher.

Peer Comparison

Quince Therapeutics, Inc. (QNCX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Quince Therapeutics, Inc. QNCX $31.85M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Quince Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Visit website →